Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth and IBS: Double Blind Randomized Controlled Trial (Multicenter Trial)

NCT00259155 is registered in ClinicalTrials.gov with Cedars-Sinai Medical Center as lead sponsor.

NCT NCT00259155
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00259155 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rifaximin in the Treatment of Small Intestinal Bacterial Overgrowth and IBS: Double Blind Randomized Controlled Trial (Multicenter Trial)
Lead sponsor
Cedars-Sinai Medical Center
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2003
Completion date
January 31, 2007
Enrollment
92
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome